HRT Financial’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

HRT Financial’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-26,030	Closed	-$2.17M	–	3600
2024 Q4	$2.17M	Sell	26,030 -140,719	-84%	-$11.6M	0.01%	708
2024 Q3	$12.2M	Sell	166,749 -73,447	-31%	-$5.52M	0.06%	203
2024 Q2	$16.5M	Buy	+240,196	New	+$16.7M	0.09%	164
2024 Q1	–	Sell	-13,767	Closed	-$985K	–	3254
2023 Q4	$985K	Buy	+13,767	New	+$792K	0.01%	991
2022 Q4	–	Sell	-10,279	Closed	-$478K	–	3310
2022 Q3	$478K	Buy	+10,279	New	+$537K	0.01%	1651
2021 Q4	–	Sell	-39,041	Closed	-$1.46M	–	4253
2021 Q3	$1.46M	Buy	+39,041	New	+$1.36M	0.01%	964
2021 Q1	–	Sell	-10,545	Closed	-$335K	–	3248
2020 Q4	$335K	Buy	+10,545	New	+$277K	0.01%	1223

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

HRT Financial's ITCI Position: Q1 2025 in Review

HRT Financial sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 26,030 shares — an estimated $2.17M sold.

HRT Financial first reported a position in ITCI in Q4 2020 and held it in 7 quarters. The position peaked at $16.5M in Q2 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

HRT Financial reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
HRT Financial sold 26,030 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $2.17M.
HRT Financial first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 7 quarters.
HRT Financial's Intra-Cellular Therapies Inc. position peaked at $16.5M in Q2 2024.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.